NASDAQ:IMDX

Oncocyte Q4 2025 Earnings Results & Report

Oncocyte logo
$1.77 -0.09 (-4.84%)
As of 03:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oncocyte reported Q4 2025 earnings on March 26, 2026. The company reported EPS of -$0.27, while revenue was $1.14 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Oncocyte EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncocyte Revenue Results

Actual Revenue
$1.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncocyte Q4 2025 Earnings FAQ

Oncocyte (NASDAQ:IMDX) reported earnings of -$0.27 per share for Q4 2025. The report was announced on Thursday, March 26, 2026.

Oncocyte reported revenue of $1.14 million for Q4 2025.

Oncocyte Earnings Headlines

IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Insight Molecular Diagnostics Announces Proposed Public Offering
iMDx to Release Third Quarter Results on November 16, 2026
Oncocyte Corporation Registered Shs
See More Oncocyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email.

About Oncocyte

Oncocyte (NASDAQ:IMDX)oration, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection.

The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

The company’s business has evolved from Oncocyte’s earlier focus on oncology diagnostics, including tests designed to help guide lung cancer treatment. Its current focus is transplant diagnostics, with services primarily directed to the U.S. healthcare market.

View Oncocyte Profile